Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke

D.C. Anthony, B. Ferguson, M.K. Matyzak, K.M. Miller, M.M. Esiri and V.H. Perry (1997) Neuropathology and Applied Neurobiology23, 406–415

[1]  J. Cossins,et al.  Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor , 1997, Journal of Neuroimmunology.

[2]  J. Newcombe,et al.  The Expression of Tissue‐type Plasminogen Activator, Matrix Metalloproteases and Endogenous Inhibitors in the Central Nervous System in Multiple Sclerosis: Comparison of Stages in Lesion Evolution , 1996, Journal of neuropathology and experimental neurology.

[3]  S. Tsirka,et al.  Neuronal cell death and tPA , 1996, Nature.

[4]  T. Tomita,et al.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas , 1996, Diseases of the colon and rectum.

[5]  S. Shapiro,et al.  Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  V. Perry,et al.  Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases , 1996, Journal of Neuroimmunology.

[7]  E Ruoslahti,et al.  Brain extracellular matrix. , 1996, Glycobiology.

[8]  C. Ford,et al.  Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis , 1996, Neurology.

[9]  Gary A. Rosenberg,et al.  Proteolytic Cascade Enzymes Increase in Focal Cerebral Ischemia in Rat , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  A. Newby,et al.  Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. , 1996, The Biochemical journal.

[11]  S. Nag.  Immunohistochemical Localization of Extracellular Matrix Proteins in Cerebral Vessels in Chronic Hypertension , 1996, Journal of neuropathology and experimental neurology.

[12]  R. Sobel,et al.  Matrix Metalloproteinases in the Normal Human Central Nervous System, Microglial Nodules, and Multiple Sclerosis Lesions , 1996, Journal of neuropathology and experimental neurology.

[13]  C. Delacourt,et al.  Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. , 1996, American journal of respiratory cell and molecular biology.

[14]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[15]  S. Chandler,et al.  Matrix metalloproteinases degrade myelin basic protein , 1995, Neuroscience Letters.

[16]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[17]  William G. Stetler-Stevenson,et al.  Tumor necrosis factor-α-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window , 1995, Brain Research.

[18]  G. Rosenberg.  Matrix metalloproteinases in brain injury. , 1995, Journal of neurotrauma.

[19]  J. Furuyama,et al.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. , 1995, Journal of neurosurgery.

[20]  R. Clark,et al.  Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor , 1995, The Journal of experimental medicine.

[21]  L. Steinman,et al.  Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. , 1994, The Journal of clinical investigation.

[22]  G. Opdenakker,et al.  Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases , 1994, Journal of Neuroimmunology.

[23]  G. Opdenakker,et al.  Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases , 1994, Journal of Neuroimmunology.

[24]  A. M. Romanic,et al.  The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent , 1994, The Journal of cell biology.

[25]  F. Sherriff,et al.  Microwave antigen retrieval of β-amyloid precursor protein immunoreactivity , 1994 .

[26]  F. Sherriff,et al.  Microwave antigen retrieval of beta-amyloid precursor protein immunoreactivity. , 1994, Neuroreport.

[27]  G. Opdenakker,et al.  Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein , 1993, Journal of neuroscience research.

[28]  B. Henderson,et al.  Rabbit models of arthritis: immunolocalization of matrix metalloproteinases and tissue inhibitor of metalloproteinase in synovium and cartilage. , 1993, The American journal of pathology.

[29]  L. Liotta,et al.  Elevated Levels of Mr 92,000 Type IV Collagenase in Human Brain Tumors , 1993 .

[30]  G. Opdenakker,et al.  Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. , 1993, Biochemical and biophysical research communications.

[31]  C. Clavel,et al.  Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. , 1993, Invasion & metastasis.

[32]  D. Rifkin,et al.  Biology and biochemistry of proteinases in tumor invasion. , 1993, Physiological reviews.

[33]  L. Liotta,et al.  Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. , 1993, Cancer research.

[34]  G. Opdenakker,et al.  Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders , 1992, Journal of Neuroimmunology.

[35]  G. Opdenakker,et al.  Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. , 1992, Cytokine.

[36]  L. Liotta,et al.  TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase , 1992, Brain Research.

[37]  R. Hembry,et al.  Proteinases in rheumatoid arthritis. , 1992, The Journal of rheumatology. Supplement.

[38]  R. Hembry,et al.  The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex. Demonstration of the biochemical similarities of tissue inhibitor of metalloproteinases-2 and tissue inhibitor of metalloproteinases-1. , 1991, The Biochemical journal.

[39]  M. Cockett,et al.  Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). , 1991, The Biochemical journal.

[40]  M. Esiri,et al.  Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. , 1991, Brain : a journal of neurology.

[41]  V. Perry,et al.  Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain , 1990, Neuroscience.

[42]  P. Stephens,et al.  Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. , 1987, The Biochemical journal.

[43]  J. Reynolds,et al.  Purification of rabbit bone inhibitor of collagenase. , 1981, The Biochemical journal.